FTD and ALS--translating mouse studies into clinical trials.

Area of Science:

• Neuroscience
• Neurology
• Translational Medicine

Background:

• Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are related neurodegenerative disorders with rapid cognitive and motor decline.
• Despite progress in understanding pathogenetic mechanisms through animal studies, translating these findings to clinical practice has been largely unsuccessful.
• A significant gap exists between preclinical research in mouse models and clinical trials in human patients.

Purpose of the Study:

• To discuss the translational gap between preclinical animal studies and clinical trials in FTD and ALS.
• To outline strategies for improving the design of preclinical studies.
• To present methods for enhancing mouse models to overcome translational shortfalls in neurodegenerative disease research.

Main Methods:

• Review of existing literature on FTD and ALS preclinical research and clinical trials.
• Analysis of the limitations of current mouse models in FTD and ALS research.
• Proposal of enhanced preclinical study designs and improved mouse models.

Main Results:

• Identification of key reasons for the lack of successful translation from animal models to human trials.
• Recommendations for optimizing preclinical study design to enhance predictive validity.
• Strategies for developing more translatable mouse models for FTD and ALS.

Conclusions:

• Improving preclinical study design and mouse models is crucial for successful drug development in FTD and ALS.
• A novel approach focusing on enhanced models and study design can improve the identification of effective therapeutics.
• This strategy holds the potential to accelerate the discovery of drugs that benefit patients with these devastating neurodegenerative diseases.